OncoMatch/Clinical Trials/NCT06633341
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma
Is NCT06633341 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies CD5 CAR T-cells for t-lymphoblastic lymphoma.
Treatment: CD5 CAR T-cells — A Clinical Study on the Safety and Effectiveness of targeting CD5 CAR-T Cells in the treatment of r/r CD5+ T-lymphoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD5 overexpression (>90%)
CD5 expression rate was >90%
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy — second-line or later
Subjects did not go into remission or relapse after receiving second-line or more chemotherapy regiments
Must have received: autologous hematopoietic stem cell transplantation
Relapse after autologous hematopoietic stem cell transplantation
Cannot have received: gene therapy
Before using any gene therapy products
Lab requirements
Kidney function
creatinine ≤176.8 (mol/L)
Liver function
Total bilirubin ≤51 (mol/L), ALT/AST ≤ 3x ULN
Cardiac function
LVEF ≥50%
Total bilirubin ≤51 (mol/L), Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) ≤ 3 times the upper limit of the normal range, creatinine ≤176.8 (mol/L); Echocardiography showed left ventricular ejection fraction (LVEF) ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify